GlassScriptPhysician profile
Matthew B Chamberlain
NPI 1831172980
$7,076.30
in general payments reported to CMS, 2019-2025
39 companies · $644 in 2025
The $644 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $1,239 · 2021: $1,858 · 2022: $708 · 2023: $763 · 2024: $763 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $995.07 | 2019-2025 | Ubrelvy, Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $743.21 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $706.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $631.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bausch Health US, LLC | $560.86 | 2019-2023 | Wellbutrin, Aplenzin |
| Astrazeneca Pharmaceuticals LP | $413.63 | 2019-2025 | Airsupra |
| Pfizer INC. | $358.96 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.81 | 2019-2024 | Jardiance, Glyxambi, Tradjenta |
| Amarin Pharma, INC. | $277.91 | 2019-2021 | |
| Allergan, INC. | $210.35 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.56 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $194.66 | 2019-2025 | Krystexxa |
| Glaxosmithkline, LLC. | $161.81 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Kowa Pharmaceuticals America, INC. | $139.99 | 2019-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $133.10 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.